Report: New Teva CEO Levin ponders the pipeline; AcelRx wins patents; China's Lotus in cash crunch;

@FierceBiotech: 'Hitchhiking' gold nanostars can sneak into cancer cells. More | Follow @FierceBiotech

@JohnCFierce: With Lipitor and Plavix out of the top 10, Abbott's Humira will take the top spot among best-sellers. Article | Follow @JohnCFierce

@RyanMFierce: An Arkansas jury rules against $JNJ in Risperdal marketing case, state AG says J&J 'lied.' Story  | Follow @RyanMFierce

> Globes reports that incoming Teva ($TEVA) CEO Jeremy Levin (photo) is taking some time to carefully review the pharma company's pipeline of experimental therapies. Levin, a veteran deal-maker at Bristol-Myers Squibb ($BMY), was brought in to beef up the company's work on novel drugs. Report

> AcelRx Pharmaceuticals has won key patents on its methods for controlling post-operative pain. Story

> China's Lotus Pharmaceuticals, a penny stock biotech company based in Beijing, says it has had to stop construction of a new headquarters after running into an unexpected cash crunch. In its release, the company made an appeal for new financing. Release

Pharma News

@FiercePharma: WSJ previews Q1 earnings. Gist: Patent cliff rules. Pfizer's 1st full Q with Lipitor rivals, Lilly's with Zyprexa. More | Follow @FiercePharma

> UPDATED: Judge hits J&J with $1.1B penalty in Risperdal case. News

> Takeda snaps up URL Pharma in $800M+ deal. Story

> Humira takes top spot in drug sales. More

> FDA adds clotting data to Bayer's Yaz, Yasmin. Article

Medical Devices News

 @FierceMedDev: Tough luck, St. Jude: No retraction for you. News | Follow @FierceMedDev

> Ex-Orthofix VP pleads guilty over kickback. Article

> Report: Diabetes Dx market to hit $32B by 2017. More

> GE touts good early data for Alzheimer's imaging Dx. Story

> Board urges evaluation of device hacking risks. Item

Biomarkers News

> Genomic sequencing--is it of value? Commentary

> Lung metastasis may be marked by tumor cell protein. More

> Scientists seek breast cancer biomarkers in a drop of blood. Article

> ARISk launched to screen for sibling autism risk. News

> Proteome Sciences shares jump on licensing deal. Item

Drug Delivery News

> Bind touts positive results for cancer-fighting nanoparticles. Article

> Natural mucoadhesive tablet delivers anti-cancer spice. Story

> Liquidia CEO: Nanotech will outpace biotech. More

> Is reformulation discouraging innovation? Piece

And Finally…Women undergoing treatment for breast cancer can experience cognitive declines, such as decreased verbal fluency or loss of memory and attention, according to a new study from the University of Missouri. Release

 

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.